The transcription factor NF-kappaB as drug target.
Haefner
Burkhard
B
Department of Inflammation, Johnson & Johnson Pharmaceutical Research and Development, A Division of Janssen Pharmaceutica, Beerse, Belgium.
D000222:Adaptation, Physiological; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000378:metabolism; D006801:Humans; D007109:Immunity / Q000502:physiology; D007249:Inflammation / Q000378:metabolism; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009369:Neoplasms / Q000378:metabolism; D009422:Nervous System Diseases / Q000378:metabolism; D009765:Obesity / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D015398:Signal Transduction / Q000502:physiology*; D014777:Virus Diseases / Q000378:metabolism
D000970:Antineoplastic Agents; D016328:NF-kappa B; D047428:Protein Kinase Inhibitors